Table 7.
Cost input included in the analysis
| Type | Description | Value | Source |
|---|---|---|---|
| Treatment acquisition | Acquisition cost – Brolucizumab (€/vial)a | €680.00a | [23, 24] |
| Acquisition cost – Aflibercept (€/vial)a | €740.00a | ||
| Number of injections, Year 1 – Brolucizumab (N/year) | 6.66 | [10, 13, 14] | |
| Number of injections, Year 1 – Aflibercept (N/year) | 7.23 | ||
| Number of injections, Year 2 – Brolucizumab (N/year) | 4.84 | ||
| Number of injections, Year 2 – Aflibercept (N/year) | 5.58 | ||
| Number of injections, Subsequent years – Brolucizumab (N/year) | 4.84 | ||
| Number of injections, Subsequent years – Aflibercept (N/year) | 5.58 | ||
| Treatment administration | Administration cost of anti-VEGF drug (€/administration) | €247.20 | Elaboration from [25] |
| Disease monitoring | Unit cost - Optical Coherence Tomography (€) | €36.07 | Elaboration from [25] |
| Resource use - Optical Coherence Tomography (N/anno) | 1.00 | ||
| TREA management | Unit cost (€) - Cataract | €994.00 | DH 039 [27] |
| Unit cost (€) - Endophthalmitis | €1522.00 | DH 042 [27] | |
| Unit cost (€) - Intraocular inflammation | €20.66 | Tariff Code 89.7 [28] | |
| Unit cost (€) - Detachment of the retina | €1491.00 | DH 036 [27] | |
| Unit cost (€) - Retinal pigment epithelial tear | €1491.00 | ||
| Unit cost (€) - Retinal tear | €1491.00 | ||
| Vision loss | Total costs direct of blindness (€) | €7856 | [26] |
| Total costs direct of low vision (€) | €1964 | ||
| Total costs (direct and indirect) of blindness (€) | €17,897 | ||
| Total costs (direct and indirect) of low vision (€) | €4474 |
DH Day hospital, TRAE Treatment-related adverse event, VEGF Vascular endothelial growth factor
aThe analysis was conducted using the ex-factory price including the mandatory legal discounts applied to public structures of the Italian NHS